Publicação
Vitrolife private equity investment committee paper - company valuation in the context of private equity
| datacite.subject.fos | Ciências Sociais::Economia e Gestão | pt_PT |
| dc.contributor.advisor | Santos, Fábio | |
| dc.contributor.author | Pollich, Emily | |
| dc.date.accessioned | 2024-11-19T11:18:34Z | |
| dc.date.available | 2024-11-19T11:18:34Z | |
| dc.date.issued | 2024-01-10 | |
| dc.date.submitted | 2023-12-20 | |
| dc.description.abstract | Vitrolife is a leading provider of in-vitro fertilization products, offering medical Consumables, Technological devices, and Genetic Testing services across the entire IVF journey. It is an attractive target for a private equity fund, given its stable EBITDA margin, strong competitive position in a high-growth market and its in-house R&D capabilities. Value creation is driven through three strategies: Eastern Europe market penetration, AI-Partnership and forward integration through the acquisition of Virtus Health. Based on an estimated exit multiple of 16.7x EBITDA, investors are expected to receive a 3.6x MM return over a six-year holding period. | pt_PT |
| dc.identifier.tid | 203604628 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10362/175491 | |
| dc.language.iso | eng | pt_PT |
| dc.relation | UID/ECO/00124/2013 | pt_PT |
| dc.subject | Private equity | pt_PT |
| dc.subject | Lbo | pt_PT |
| dc.subject | Acquisition | pt_PT |
| dc.subject | Vitrolife | pt_PT |
| dc.subject | Leverage buyout | pt_PT |
| dc.subject | Healthcare | pt_PT |
| dc.title | Vitrolife private equity investment committee paper - company valuation in the context of private equity | pt_PT |
| dc.type | master thesis | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | masterThesis | pt_PT |
| thesis.degree.name | A Work Project, presented as part of the requirements for the Award of a Master’s degree in Finance from the Nova School of Business and Economics. | pt_PT |